profit from every $100 of sales.
$0$100
Black Diamond Therapeutics
$1.47-3.29% today
-67.3% in 1 year
1-year low $1.471-year high $4.49
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $3.78 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Black Diamond Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $70.0 million in 2025, with $22.4 million of profit last year.
SalesProfit
Black Diamond Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Black Diamond Therapeutics | 3.8× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Black Diamond Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 70 | |
| – | – | – | – | |
| -93 | -86 | -79 | 20 | |
| -92 | -86 | -78 | 20 | |
| -91 | -82 | -70 | 22 | |
| -2.52 | -1.88 | -1.27 | 0.39 | |
| – | – | – | – | |
| – | – | – | 28.4% | |
| – | – | – | 32.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 156 | 159 | 123 | 143 |
| Cash | 34 | 56 | 36 | 21 |
| Total debt | 28 | 25 | 22 | 19 |
| Total liabilities | 41 | 42 | 39 | 31 |
| 116 | 117 | 83 | 112 | |
| 36 | 44 | 55 | 58 | |
| -51.0% | -48.1% | -59.0% | 12.0% | |
| -78.8% | -70.6% | -83.7% | 19.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -85 | -67 | -62 | 30 | |
| 0 | 0 | – | – | |
| -85 | -67 | -62 | 30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 10 | 11 | 7 |
Valuation
- 3.8×
- –
- –
- 2.0×
- 1.2×
- 2.9×
- 4.1×
- 35.1%
- 26.5%
- 0.0%
Profitability
- 0.0%
- 28.4%
- 32.0%
- 0.0%
- -43.6%
- -45.2%
- -36.4%
- -32.5%
- -45.0%
- –
Growth
- –
- –
- +147.5%
- –
- +12.0%
Financial health
- 0.3×
- 0.17
- 13.5%
- –
- 8.46
- 8.46
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 952
Top 10%of 884
Top 2%of 601
Top 1%of 987
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.16 | -0.18 | +11.1% |
| Mar 16, 2026 | -0.14 | -0.18 | +22.2% |
| Nov 6, 2025 | -0.15 | -0.22 | +31.8% |
| Aug 7, 2025 | -0.19 | -0.25 | +24.0% |
| May 12, 2025 | 0.98 | 0.02 | +4,800.0% |
| Mar 6, 2025 | -0.28 | -0.31 | +9.7% |
| Nov 5, 2024 | -0.28 | -0.37 | +24.3% |
| Aug 6, 2024 | -0.36 | -0.39 | +7.7% |
News
Microsoft Service Outage Give Software Giant Black EyeYahoo Finance · Nov 13, 2026Black Rock Coffee Bar raises its full-year store growth targetSeeking Alpha · Nov 11, 2026A prolonged war in Iran is the market’s real ‘black swan,’ says this strategistMarketWatch · Nov 5, 2026Should You Be Worried About Stanley Black & Decker Stock?Yahoo Finance · Oct 29, 2026Black Stone Minerals declares $0.30 dividendSeeking Alpha · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
73Pass
Philip Fisher
59No pass
Peter Lynch
100Pass
Joel Greenblatt
64Pass
Charlie Munger
54No pass
Terry Smith
53No pass
Questions about Black Diamond Therapeutics
Is Black Diamond Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Black Diamond Therapeutics AI analysis
What does Black Diamond Therapeutics do?
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It is in Biotechnology.
Does Black Diamond Therapeutics pay a dividend?
No. Black Diamond Therapeutics does not pay a dividend at the moment.
Is Black Diamond Therapeutics stock halal?
No. Black Diamond Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 152% of its market value, at or above the 33% limit. How we check
How has Black Diamond Therapeutics stock done over the past year?
Down 67.3% over the past twelve months, to $1.47. It traded between $1.47 and $4.49 and is 67.3% below its high.
Who are Black Diamond Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Black Diamond Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.